BioSpace News Archive

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that its Senior Vice President and Chief People Officer, Carla Poulson, has been named one of Savoy Magazine’s 2022 Most Influential Black Executives in Corporate America.

Renovia Inc. (Renovia), a developer of non-surgical treatments for female pelvic floor disorders and an advocate for women’s health, announced today that Neurourology and Urodynamics published two studies demonstrating low rates of documented adherence to treatment guidelines.

The second quarter of 2022 provided the latest data point to confirm IRRAS’ progress toward becoming a leader in neurocritical care.

BioElectronics Corporation announced via a Shareholder’s update that the Company has completed and undertaken additional clinical research and has received the initial stocking purchase order from its distribution partner, Stada.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Commission (EC) adopted a positive opinion on the fulfillment of the last specific obligation and recommended the granting of Marketing Authorization (MA) for Veklury® (remdesivir) that is no longer subject to specific obligations.

Kite’s CAR T-cell Therapy Tecartus ® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL).

The U.S. Food and Drug Administration prioritizes the health and safety of American consumers and patients as well as animals and uses a variety of tools for the appropriate oversight of FDA-regulated products and establishments.

The global Blood Glucose Monitoring Devices market size is expected to be worth around US$ 23.5 billion by 2030 from valued at US$ 12.70 billion in 2020 and is anticipated to grow at a CAGR of 7.10% from 2022 to 2030.

The global clinical laboratory services market size was valued at US$ 238 billion in 2021 and is expected to reach US$ 415 billion by 2030 with a CAGR of 6.5% from 2022 to 2030.

According to Research Study, global glycomics market size is expected to reach around USD 3.5 billion by 2030 and is anticipated to grow at a CAGR of 14.10% during forecast period 2022 to 2030.